JP2025511969A5 - - Google Patents

Info

Publication number
JP2025511969A5
JP2025511969A5 JP2024559691A JP2024559691A JP2025511969A5 JP 2025511969 A5 JP2025511969 A5 JP 2025511969A5 JP 2024559691 A JP2024559691 A JP 2024559691A JP 2024559691 A JP2024559691 A JP 2024559691A JP 2025511969 A5 JP2025511969 A5 JP 2025511969A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
combination
optionally
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065433 external-priority patent/WO2023196899A2/en
Publication of JP2025511969A publication Critical patent/JP2025511969A/ja
Publication of JP2025511969A5 publication Critical patent/JP2025511969A5/ja
Pending legal-status Critical Current

Links

JP2024559691A 2022-04-08 2023-04-06 Pi3キナーゼ阻害剤とチェックポイント阻害剤の併用を用いた、多形膠芽腫、及び乳癌を含むその他の癌をスクリーニング及び治療するための方法及び製品 Pending JP2025511969A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329096P 2022-04-08 2022-04-08
US63/329,096 2022-04-08
US202263368499P 2022-07-15 2022-07-15
US63/368,499 2022-07-15
PCT/US2023/065433 WO2023196899A2 (en) 2022-04-08 2023-04-06 Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2025511969A JP2025511969A (ja) 2025-04-16
JP2025511969A5 true JP2025511969A5 (cg-RX-API-DMAC7.html) 2026-04-14

Family

ID=88243701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559691A Pending JP2025511969A (ja) 2022-04-08 2023-04-06 Pi3キナーゼ阻害剤とチェックポイント阻害剤の併用を用いた、多形膠芽腫、及び乳癌を含むその他の癌をスクリーニング及び治療するための方法及び製品

Country Status (9)

Country Link
US (1) US20250228863A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504264A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025511969A (cg-RX-API-DMAC7.html)
KR (1) KR20250044594A (cg-RX-API-DMAC7.html)
CN (1) CN119654165A (cg-RX-API-DMAC7.html)
AU (1) AU2023249640A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255739A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024012457A (cg-RX-API-DMAC7.html)
WO (1) WO2023196899A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
RU2016148441A (ru) * 2014-05-21 2018-06-22 Ф. Хоффманн-Ля Рош Аг Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2020215037A1 (en) * 2019-04-18 2020-10-22 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer

Similar Documents

Publication Publication Date Title
Marei et al. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Mun et al. Tumor-treating fields: a fourth modality in cancer treatment
O'Donnell et al. The promise of neoadjuvant immunotherapy and surgery for cancer treatment
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
Katz et al. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
DuRoss et al. Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer
Berenson et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study
EP2359828A1 (en) HDAC inhibitors and hormone targeted drugs for the treatment of cancer
JP2022082565A (ja) がんを処置するための方法
Wilson et al. Advanced basal cell carcinoma: what dermatologists need to know about treatment
Li et al. The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
EP4376828A1 (en) Combination therapy for treating abnormal cell growth
JP2022022392A (ja) ヒトにおける固形腫瘍の処置のためのC.novyi
Kunos et al. Long-term disease control with triapine-based radiochemotherapy for patients with stage IB2–IIIB cervical cancer
Curigliano et al. Alpelisib in combination with everolimus±exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
JP2019510785A (ja) 癌を処置する方法
Kuboki et al. PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study
Inetas‐Yengin et al. Related mechanisms, current treatments, and new perspectives in meningioma
Zhou et al. Therapeutic potential of tumor treating fields for malignant brain tumors
Lee et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study
Kurdi et al. Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors
Li et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
Kunos et al. Phase I trial of triapine–cisplatin–paclitaxel chemotherapy for advanced stage or metastatic solid tumor cancers
KR20110128916A (ko) 췌장암의 치료
Khan et al. Intermittent MEK inhibition for the treatment of metastatic uveal melanoma